Showing results (11-20 of 104) with videos related to
Sort By:
Pageof 11
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Research on the Ratio of Anti-Cancer Drug Purchase Costs at Municipal Hospitals in the Aichi Prefecture]Hiroaki Sakurada, Kazuyuki Naito, Hitomi TeramachiBriefings in Bioinformatics|August 28, 2021
Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data sourceYoshihiro Noguchi, Tomoya Tachi, Hitomi TeramachiMolecular and Clinical Oncology|February 18, 2020
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinomaMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Anticancer Research|June 4, 2021
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal CancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Oncology Letters|January 3, 2022
Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuriaMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Journal of Clinical Medicine|September 9, 2022
Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database StudyYoshihiro Noguchi, Shunsuke Yoshizawa, Tomoya Tachi, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 2, 2008
[Evaluation of the cardio pulmonary resuscitation/automated external defibrillator class and disability experiences class provided as part of the early exposure program]Eiji Sakai, Hitomi Teramachi, Hiroyuki Nishida, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 25, 2017
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Anticancer Research|March 6, 2020
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal CancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Anticancer Research|February 4, 2019
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal CancerMichio Kimura, Eiseki Usami, Hitomi Teramachi, et al.Pageof 11